当前位置：
X-MOL 学术
›
Rheumatology
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Risk factors of COVID-19 related hospitalization of pediatric patients with rheumatic diseases: a systematic review and meta-analysis
Rheumatology ( IF 4.7 ) Pub Date : 2024-12-10 , DOI: 10.1093/rheumatology/keae664 Qianzi Zhao, Beth Wallace, Tova Ronis, Lawrence Jung
Rheumatology ( IF 4.7 ) Pub Date : 2024-12-10 , DOI: 10.1093/rheumatology/keae664 Qianzi Zhao, Beth Wallace, Tova Ronis, Lawrence Jung
Objective Among adults who develop Coronavirus Disease 2019 (COVID-19), those with rheumatic diseases (RDs) have similar hospitalization rates compared with those without RDs. Similar comparisons are lacking in children, due to the overall rarity of COVID-19-related hospitalization in this population. We aimed to examine the risk factors for COVID-19-related hospitalization in pediatric patients with RDs. Methods We conducted a systemic literature search in MEDLINE, EMBASE, Web of Science, and China National Knowledge Infrastructure from December 1, 2019, through January 22, 2024. We included observational studies based on inclusion and exclusion criteria. ORs with 95% confidence intervals (95% CIs) were calculated. Results Eight cohort studies capturing 1,501 pediatric RD patients with SARS-CoV-2 and 118 COVID-19-related hospitalization were included. Odds of hospitalization was increased in children with RDs compared with healthy children. While the diagnosis of juvenile idiopathic arthritis (JIA) was associated with reduced odds of hospitalization overall (OR 0.43, [95% CI, 0.27–0.68]), systemic JIA was associated with increased odds of hospitalization (OR 2.54, [95% CI, 1.01–6.40]). The use of glucocorticoids (OR 5.36; 95% CI [2.21–13.04]), rituximab (OR 4.62, [95% CI, 1.87–11.40]), mycophenolate (OR 4.17, [95% CI, 1.08–16.16], hydroxychloroquine (OR 2.97, [95% CI, 1.42–6.21], and IL-1-inhibitors (OR 2.28, [95% CI, 1.09–4.78]) were associated with increased odds of hospitalization, while the use of TNFα-inhibitors was associated with reduced odds (OR 0.35, [95% CI, 0.20–0.66]). Conclusion Children with RDs are at risk of severe COVID-19 outcomes, while children with JIA taking TNFα-inhibitors might be at a lower risk.
更新日期：2024-12-10
京公网安备 11010802027423号